No OS benefit with tasquinimod in mCRPC

13/06/2016 - 21:00
The oral immunotherapy tasquinimod improved radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer ... More »
Visit website
Field of Interest: Oncology
News Feed: Internal Medicine News - Oncology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness